Enanta Pharmaceuticals Inc ENTA:NASDAQ

Last Price$49.84Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 5/13/22
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$23.21 (100)
Ask (Size)$83.79 (100)
Day Low / HighN/A - N/A
Volume272.4 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/13/2022

 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $49.84
Change: -0.04 (0.08%)
Volume: 272.4 K
3:59PM ET 5/13/2022
 
 

Veru Inc ( NASDAQ )

Price: $13.00
Change: +3.97 (43.96%)
Volume: 397.8 K
6:34PM ET 5/13/2022
 
 

Amneal Pharmaceuticals Inc ( NYSE )

Price: $3.43
Change: -0.02 (0.58%)
Volume: 37.00
4:00PM ET 5/13/2022
 
 

Revance Therapeutics Inc ( NASDAQ )

Price: $13.90
Change: +0.01 (0.11%)
Volume: 857.2 K
4:23PM ET 5/13/2022
 
 

Crinetics Pharmaceuticals Inc ( NASDAQ )

Price: $18.77
Change: +0.02 (0.11%)
Volume: 331.8 K
4:00PM ET 5/13/2022
 

Read more news Recent News

Roth Capital Adjusts Enanta Pharmaceuticals' Price Target to $70 From $101, Reiterates Buy Rating
5:20AM ET 5/12/2022 MT Newswires

Enanta Pharmaceuticals (ENTA) has an average rating of outperform and price targets ranging from $35 to $130, according to analysts polled by Capital IQ....

--Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $70 From $73, Maintains Perform Rating
10:47AM ET 5/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--SVB Securities Lowers Enanta Pharmaceuticals Price Target to $58 From $68, Maintains Market Perform Rating
11:39AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--JMP Securities Lowers Enanta Pharmaceuticals Price Target to $114 From $116, Maintains Market Outperform Rating
10:36AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionEnanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA. View company web site for more details
Address500 Arsenal Street
Watertown, Massachusetts 02472
Phone+1.617.607.0800
Number of Employees113
Recent SEC Filing05/09/20228-K
President, Chief Executive Officer & DirectorJay R. Luly
CFO & Senior VP-Finance & AdministrationPaul J. Mellett
CSO, Senior Vice President-Research & DevelopmentYat Sun Or
Chief Medical Officer & Senior Vice PresidentNathalie Adda

Company Highlights

Price Open$51.64
Previous Close$49.88
52 Week Range$40.37 - 102.00
Market Capitalization$1.0 B
Shares Outstanding20.7 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$5.52
Beta vs. S&P 500N/A
Revenue$206.6 M
Net Profit Margin-122.68%
Return on Equity-28.80%

Analyst Ratings as of 05/12/2022

Buy
5
Overweight
1
Hold
3
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset